Overview:

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the most rapidly spreading disease since 2020. The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits S1 and S2, facilitates viral genome entry into the host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) (1). The UK variant B.1.1.7 contains 9 out of 23 mutations in the Spike protein region. Of the mutations identified in the UK variant, D614G has been associated with higher viral infectivity and N501Y is known to increase affinity for ACE2 protein. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (2, 3).

Gene Aliases:

2019-nCoV s1, SARS-CoV-2 spike S1, SARS-CoV-2 S1, novel coronavirus spike s1, nCov spike s1, coronavirus spike S1.

Genebank Number:

MN908947

Formulation:

Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole.

References:

1. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. Nature. 2020, 581:215-220. 2. Tada T, et al: Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1. 3. Korber B, et al: Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the covid-19 virus. Cell. 2020, 182:812-82.